Cellular and T cell engager Immunotherapy
Prompt and Profound Responses with Talquetamab in Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma – Another bridging therapy
Shebli Atrash, MD
hematology & oncology
Levine Cancer Institute
Charlotte, North Carolina, United States